ACTRN12622000699763已完成未知
The feasibility and impact of HPV-based cervical screening incorporating the choice of a vaginal self-test in the NZ primary care setting
Otago University0 个研究点目标入组 3,311 人开始时间: 2022年5月16日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3,311
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
入排标准
- 年龄范围
- 20 Years 至 o limit（—）
- 性别
- All
入选标准
- •People enrolled in the practice who are eligible for cervical screening as part of the National Cervical Screening Programme (NCSP)* and are recalled for cervical screening or opportunistically attend the provider and are due for a cervical screen within the study enrolment period.
- •Patients who are recalled for screening but report symptoms at the time of their screening test will be eligible for the study, however a strong recommendation for a clinical assessment will be made.
- •Patients who are invited to participate in this study can do so if they agree to participate within 3 months of the completion of the recruitment period (i.e., before 1 April 2023).
- •*For full details of inclusion for NCSP screening, please refer to the 2020 Ministry of Health Clinical Practice Guidelines for Cervical Screening in New Zealand at www.nsu.govt.nz.
排除标准
- •Patients who are unable or unwilling to provide informed consent.
研究者
相似试验
进行中（未招募）
不适用
HPV infection clearance with glucan and probioticsISRCTN62596811Ospedale dei Bambini Vittore Buzzi80
已完成
不适用
HPV DNA Testing Through Mobile Mammography UnitCervical CancerNCT03551028University of Virginia33
已完成
不适用
Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay NavigatorsHuman Papilloma VirusNCT03139669University of Virginia100
已完成
3 期
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of AgeInfections, PapillomavirusNCT00492544GlaxoSmithKline100
已完成
1 期
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 YrsInfections, PapillomavirusNCT00541970GlaxoSmithKline961